These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 25412509)

  • 21. Biochemical characterization of cholesteryl ester transfer protein inhibitors.
    Ranalletta M; Bierilo KK; Chen Y; Milot D; Chen Q; Tung E; Houde C; Elowe NH; Garcia-Calvo M; Porter G; Eveland S; Frantz-Wattley B; Kavana M; Addona G; Sinclair P; Sparrow C; O'Neill EA; Koblan KS; Sitlani A; Hubbard B; Fisher TS
    J Lipid Res; 2010 Sep; 51(9):2739-52. PubMed ID: 20458119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of cholesteryl ester transfer protein by anacetrapib does not impair the anti-inflammatory properties of high density lipoprotein.
    Han S; Levoci L; Fischer P; Wang SP; Gagen K; Chen Y; Xie D; Fisher T; Ehrhardt AG; Peier AM; Johns DG
    Biochim Biophys Acta; 2013 Apr; 1831(4):825-33. PubMed ID: 23269286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
    Masson D
    Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
    Niesor EJ
    Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.
    Niesor EJ; Magg C; Ogawa N; Okamoto H; von der Mark E; Matile H; Schmid G; Clerc RG; Chaput E; Blum-Kaelin D; Huber W; Thoma R; Pflieger P; Kakutani M; Takahashi D; Dernick G; Maugeais C
    J Lipid Res; 2010 Dec; 51(12):3443-54. PubMed ID: 20861162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E.
    Millar JS; Lassman ME; Thomas T; Ramakrishnan R; Jumes P; Dunbar RL; deGoma EM; Baer AL; Karmally W; Donovan DS; Rafeek H; Wagner JA; Holleran S; Obunike J; Liu Y; Aoujil S; Standiford T; Gutstein DE; Ginsberg HN; Rader DJ; Reyes-Soffer G
    J Lipid Res; 2017 Jun; 58(6):1214-1220. PubMed ID: 28314859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative studies of three cholesteryl ester transfer proteins and their interactions with known inhibitors.
    Wang Z; Niimi M; Ding Q; Liu Z; Wang L; Zhang J; Xu J; Fan J
    PLoS One; 2017; 12(8):e0180772. PubMed ID: 28767652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of the Bound Phospholipids in the Structural Stability of Cholesteryl Ester Transfer Protein.
    Revanasiddappa PD; Sankar R; Senapati S
    J Phys Chem B; 2018 Apr; 122(15):4239-4248. PubMed ID: 29587476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural Plasticity of Cholesteryl Ester Transfer Protein Assists the Lipid Transfer Activity.
    Chirasani VR; Revanasiddappa PD; Senapati S
    J Biol Chem; 2016 Sep; 291(37):19462-73. PubMed ID: 27445332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.
    Reyes-Soffer G; Millar JS; Ngai C; Jumes P; Coromilas E; Asztalos B; Johnson-Levonas AO; Wagner JA; Donovan DS; Karmally W; Ramakrishnan R; Holleran S; Thomas T; Dunbar RL; deGoma EM; Rafeek H; Baer AL; Liu Y; Lassman ME; Gutstein DE; Rader DJ; Ginsberg HN
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):994-1002. PubMed ID: 26966279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-based mechanism and inhibition of cholesteryl ester transfer protein.
    Xue H; Zhang M; Liu J; Wang J; Ren G
    Curr Atheroscler Rep; 2023 Apr; 25(4):155-166. PubMed ID: 36881278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insights into the Tunnel Mechanism of Cholesteryl Ester Transfer Protein through All-atom Molecular Dynamics Simulations.
    Lei D; Rames M; Zhang X; Zhang L; Zhang S; Ren G
    J Biol Chem; 2016 Jul; 291(27):14034-14044. PubMed ID: 27143480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.
    Krishna R; Anderson MS; Bergman AJ; Jin B; Fallon M; Cote J; Rosko K; Chavez-Eng C; Lutz R; Bloomfield DM; Gutierrez M; Doherty J; Bieberdorf F; Chodakewitz J; Gottesdiener KM; Wagner JA
    Lancet; 2007 Dec; 370(9603):1907-14. PubMed ID: 18068514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for a role of CETP in HDL remodeling and cholesterol efflux: role of cysteine 13 of CETP.
    Maugeais C; Perez A; von der Mark E; Magg C; Pflieger P; Niesor EJ
    Biochim Biophys Acta; 2013 Nov; 1831(11):1644-50. PubMed ID: 23872476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
    Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
    J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis.
    Trinder M; Wang Y; Madsen CM; Ponomarev T; Bohunek L; Daisely BA; Julia Kong H; Blauw LL; Nordestgaard BG; Tybjærg-Hansen A; Wurfel MM; Russell JA; Walley KR; Rensen PCN; Boyd JH; Brunham LR
    Circulation; 2021 Mar; 143(9):921-934. PubMed ID: 33228395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction of In-Stent Restenosis by Cholesteryl Ester Transfer Protein Inhibition.
    Wu BJ; Li Y; Ong KL; Sun Y; Shrestha S; Hou L; Johns D; Barter PJ; Rye KA
    Arterioscler Thromb Vasc Biol; 2017 Dec; 37(12):2333-2341. PubMed ID: 29025709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anacetrapib: hope for CETP inhibitors?
    Gurfinkel R; Joy TR
    Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural and biophysical insight into cholesteryl ester-transfer protein.
    Hall J; Qiu X
    Biochem Soc Trans; 2011 Aug; 39(4):1000-5. PubMed ID: 21787337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis.
    Wu BJ; Shrestha S; Ong KL; Johns D; Dunn LL; Hou L; Barter PJ; Rye KA
    Int J Cardiol; 2015 Nov; 199():204-12. PubMed ID: 26204569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.